अApnaFunda
Menu

SAT KARTAR LIFE LIMITED (SATKARTAR)

Health Technology · Pharmaceuticals: Other · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.96 / 100
Profitability 93Balance sheet 100

Passes these screensQuality CompounderValue PickDebt-light & profitable

Compare withCIPLAAUROBINDO PHARMALUPIN

Share price

Closing priceAdjusted for splits and bonus issues.

₹155.05 latest close · +4.8% over the last 90 sessions

₹125₹150₹175₹200Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹125₹150₹175₹200Jul 3Sep 4Nov 9

₹155.05 month-end · −13.3% over 12 months

₹125₹150₹175₹200Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹125₹150₹175₹200Nov '25May '26Nov '26

₹155.05 month-end · −20.4% since Jun '25

₹125₹150₹175₹200Jun '25Sep '25Jan '26Apr '26Aug '26Nov '26 ₹125₹150₹175₹200Jun '25Mar '26Nov '26

52-week range ₹110.30 to ₹219.80 · 1-year volatility 58.0%

Was the rally earned?

-13%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 52 points, but investors now pay less per rupee of profit (P/E 28.7x to 14.3x), which took 65 points back.
  • The share count barely moved.
Net profit growth: +50 pts. Points of the price return explained by net profit growing (or shrinking).+50 ptsNet profit growthP/E change: −65 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−65 ptsP/E changeShare count change: +2 pts. Points of the price return explained by the share count changing. More shares count against the price.+2 ptsShare count changeShare price: −13%−13%Share priceNet profit growth: +50 pts. Points of the price return explained by net profit growing (or shrinking).+50ProfitP/E change: −65 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−65P/EShare count change: +2 pts. Points of the price return explained by the share count changing. More shares count against the price.+2SharesShare price: −13%−13%Share price
Net profit growth+50 ptsNet profit rose about 71%, which lifts the price.
P/E change-65 ptsThe P/E fell from 28.7x to 14.3x, which lowers the price.
Share count change+2 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with CIPLA

How rough has the ride been?

Maximum drawdown-49.0%not yet recovered
1-year volatility58.0%annualised

Drawdown from peak

0%−20%−40%2026−49.0% 0%−20%−40%2026−49.0%
Largest drawdowns

-49.0% (2025-02 peak to 2026-09 low, not yet recovered)

-16.5% (2025-01 peak to 2025-01 low, recovered 2025-02)

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE93rd
  • Revenue growth75th
  • EPS growth84th
  • Debt/equity ↓81st▲ 19 pts vs a year ago
  • Cash cycle ↓96th▲ 6 pts vs a year ago
  • P/E ↓86th▲ 29 pts vs a year ago
  • 12M momentum23rd

Rank history

ROCE
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~11%annual earnings growth implied by the price

At a P/E of 14.3x, the price would imply about 10.8%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹155.05
P/E
14.3x
ROCE
36.0%
Market Cap
₹245 cr
Revenue (TTM)
₹201 cr
P/S
1.2x
P/B
3.6x
ROE
25.2%
Debt / Equity
0.0x
Promoter Holding
63.6%
12M Momentum
-13.3%

52-week range

₹110.30₹219.80
41% of the way from its 52-week low to its high

Price risk

1Y volatility
58.0%
Beta vs sector
1-year daily
0.96

Balance sheet & cash

Interest cover
operating profit ÷ interest
24.0x
Share count, 1Y
unchanged

Are profits backed by cash?

1 of 1checks within rangeAll clear
Other income reliance9%Within range

Other income as a share of pre-tax profit (trailing twelve months): 8.7%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow—Not enough data

Not enough reported data to compute this.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress—Not enough data

Not enough reported data to compute this.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

What happened next to similar setups

−3.2%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like SAT KARTAR LIFE LIMITED today on valuation, return on capital, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −27% to +17% vs the market, against −2% for all non-financial companies in the same months.
  • The gap against the base rate (−1.0%, 80% range −16.5% to +10.6%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
DEVIT · Feb 2025: −57.9% vs market
ZEAL · Apr 2025: −55.7% vs market
SHREEOSFM · Sep 2025: −55.3% vs market
TOLINS · Sep 2025: −50.9% vs market
SRHHYPOLTD · Jul 2023: −43.7% vs market
GULPOLY · May 2023: −41.8% vs market
BALAXI · Nov 2022: −37.9% vs market
INDRAMEDCO · May 2021: −35.6% vs market
DRCSYSTEMS · Sep 2025: −34.9% vs market
APOLSINHOT · May 2021: −34.1% vs market
LINC · Aug 2025: −32.4% vs market
RADHIKAJWE · Aug 2025: −32.3% vs market
MYMUDRA · Sep 2025: −28.1% vs market
PANAMAPET · Mar 2023: −23.4% vs market
INTENTECH · May 2022: −23.3% vs market
ALANKIT · Jan 2021: −23.2% vs market
GTPL · Jul 2021: −23.0% vs market
DSSL · Mar 2025: −21.8% vs market
EFACTOR · Jun 2025: −19.6% vs market
QUESTLAB · Aug 2025: −18.0% vs market
PARTYCRUS · Mar 2025: −17.8% vs market
KRITINUT · May 2025: −14.7% vs market
STEELCAS · Jun 2023: −6.4% vs market
MPSLTD · Sep 2021: −5.6% vs market
AKSHARCHEM · Jun 2020: −3.9% vs market
FIEMIND · Jun 2023: −2.5% vs market
CIGNITITEC · Aug 2021: −0.7% vs market
CYBERTECH · Jan 2024: +0.7% vs market
WOL3D · Oct 2025: +3.2% vs market
ICEMAKE · Mar 2020: +11.7% vs market
FIBERWEB · Jun 2024: +12.2% vs market
DLINKINDIA · Dec 2020: +13.3% vs market
EXPLEOSOL · Oct 2021: +13.6% vs market
LUMAXTECH · May 2020: +14.4% vs market
MUNJALAU · Mar 2020: +15.5% vs market
ALLDIGI · Feb 2021: +16.3% vs market
GANECOS · Oct 2020: +16.7% vs market
DPWIRES · Feb 2023: +17.4% vs market
PREMIERPOL · Jun 2024: +21.1% vs market
JAMNAAUTO · Jan 2020: +22.1% vs market
ACCENTMIC · Dec 2024: +28.1% vs market
SAKSOFT · Jul 2021: +35.1% vs market
PPL · Sep 2020: +36.2% vs market
CHEMFAB · May 2024: +39.3% vs market
MOLDTECH · May 2021: +58.9% vs market
KRISHANA · Jul 2020: +90.1% vs market
RSYSTEMS · Oct 2022: +93.4% vs market
SHYAMCENT · Jun 2021: +98.4% vs market
ASAHISONG · Mar 2020: +139.9% vs market
BEPL · May 2020: +150.6% vs market
Similar setups −3.2%All companies −2.2%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
−3.2%
All companies' median
−2.2%
Beat the market
46% vs 48%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
INTENTECH
Technology Services		 May 2022 9x31% +20%−34% −23%
PARTYCRUS
Consumer Services		 Mar 2025 20x29% −12%−32% −18%
EXPLEOSOL
Technology Services		 Oct 2021 20x39% +108%−17% +14%
SAKSOFT
Technology Services		 Jul 2021 15x24% +175%−6% +35%
PPL
Producer Manufacturing		 Sep 2020 6x29% +2%−14% +36%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
DPWIRES
Producer Manufacturing		 Feb 2023 16x28% +16%−26% +17%
EFACTOR
Commercial Services		 Jun 2025 15x38% −1%−29% −20%
ALLDIGI
Technology Services		 Feb 2021 11x25% +36%−7% +16%
How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, 12-month momentum and drawdown from 12-month high. Not used (unavailable for this company): operating margin. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SAT KARTAR LIFE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

3 events since Dec '25

  1. SepPriceFell 49% from the Feb 2025 peak to the Sep 2026 low.
  2. JunResultsRevenue (TTM) reached a new high of ₹201 cr.
  3. DecInstitutionsFII + DII holding fell 6.5 pts over 1 quarter to 3.5%.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history18 months · 2025-06 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1114.3x₹201 cr25.2%36.0%0.0x
2026-1012.0x₹201 cr25.0%36.0%0.0x
2026-0917.9x₹201 cr25.0%36.0%0.0x
2026-0811.5x₹201 cr25.0%36.0%0.0x
2026-0711.9x₹201 cr25.0%36.0%0.0x
2026-0613.4x₹201 cr25.0%36.0%0.0x
2026-0529.0x₹163 cr19.2%—0.1x
2026-0431.4x₹163 cr19.2%—0.1x
2026-0324.1x₹163 cr19.2%—0.1x
2026-0228.2x₹163 cr19.2%—0.1x
2026-0123.5x₹163 cr19.2%—0.1x
2025-1222.9x₹163 cr19.2%—0.1x
2025-1128.7x₹163 cr19.2%—0.1x
2025-1031.2x₹163 cr19.2%—0.1x
2025-0924.8x₹163 cr19.2%—0.1x
2025-0827.4x₹163 cr19.2%—0.1x
2025-0728.6x₹163 cr19.2%—0.1x
2025-0631.2x₹163 cr19.2%—0.1x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback